DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
DURECT Corp (DRRX) Tops Q2 EPS by 7c
August 3, 2020 4:52 PM EDTDURECT Corp (NASDAQ: DRRX) reported Q2 EPS of $0.07, $0.07 better than the analyst estimate of $0.00. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $11.48 million.
"We continued to make progress in our clinical programs investigating DUR-928, our lead epigenetic... More
